About Dyadic
Dyadic is a company based in Jupiter (United States) founded in 1979. The company has 6 employees as of December 31, 2024. Dyadic offers products and services including C1 Platform, Dapibus™ Platform, and Vaccines and Antibodies. Dyadic operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Jupiter, United States
- Employees 6 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dyadic International, Inc.
-
Annual Revenue
$3.5 M (USD)20.58as on Dec 31, 2024
-
Net Profit
-$5.81 M (USD)14.51as on Dec 31, 2024
-
EBITDA
-$5.88 M (USD)28.24as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
European Commission
& 3 more
-
Employee Count
6
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Dyadic
Dyadic is a publicly listed company on the NASDAQ with ticker symbol DYAI in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Dyadic
Dyadic offers a comprehensive portfolio of products and services, including C1 Platform, Dapibus™ Platform, and Vaccines and Antibodies.
Platform for producing industrial enzymes and therapeutic proteins efficiently
System for low-cost proteins in food, nutrition, and biopharmaceutical applications
Recombinant products for human and animal health treatments
People of Dyadic
Unlock access to complete
Unlock access to complete
Leadership Team
9 people
Finance and Accounting
2 people
Sales and Marketing
1 people
Staff Team
1 people
Unlock access to complete
Funding Insights of Dyadic
Investors in Dyadic
Dyadic has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Commission, Brean Capital and Crestview Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment firm focusing on partnerships, business strategy, and value addition through experience.
|
Locked | Locked | Locked | |
|
Institution of the European Union responsible for upholding the EU treaties
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Dyadic
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dyadic
Investment portfolio details for Dyadic
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dyadic
Detailed financials for Dyadic
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dyadic Comparisons
Peer comparison for Dyadic
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dyadic
Dyadic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Dyadic
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dyadic
Complete news archive for Dyadic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dyadic
Dyadic was founded in 1979 and raised its 1st funding round 25 years after it was founded.
Dyadic is headquartered in Jupiter, United States. It is registered at Jupiter, Florida, United States.
As of Dec 31, 2024, the latest employee count at Dyadic is 6.
Annual revenue of Dyadic is $3.5M as on Dec 31, 2024.
Dyadic was founded in 1979 and is based in Jupiter, United States. Microbial platforms are developed for industrial and therapeutic uses within the biotechnology sector. The proprietary C1 expression system is refined and applied to support protein production for vaccines and pharmaceuticals. Operations emphasize scalable solutions for bringing biologics to market, with activities centered on expression technology advancements.
Dyadic's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Dyadic offers C1 Platform, Dapibus™ Platform, and Vaccines and Antibodies.
Yes, Dyadic is publicly traded on NASDAQ under the ticker symbol DYAI.
Dyadic has 4 investors. Key investors include European Commission, Brean Capital, Crestview Partners, and Mercantile Capital.
The ticker symbol of Dyadic is DYAI on NASDAQ.